Related references
Note: Only part of the references are listed.Phase 1 Radioimmunotherapy Study with Lutetium 177-labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma
Alexander B. Stillebroer et al.
EUROPEAN UROLOGY (2013)
Molecular characterization of mucinous ovarian tumours supports a stratified treatment approach with HER2 targeting in 19% of carcinomas
Michael S. Anglesio et al.
JOURNAL OF PATHOLOGY (2013)
Survival for Ovarian Cancer in Europe: The across-country variation did not shrink in the past decade
Willi Oberaigner et al.
ACTA ONCOLOGICA (2012)
Downregulation of membrane complement inhibitors CD55 and CD59 by siRNA sensitises uterine serous carcinoma overexpressing Her2/neu to complement and antibody-dependent cell cytotoxicity in vitro: implications for trastuzumab-based immunotherapy
S. Bellone et al.
BRITISH JOURNAL OF CANCER (2012)
Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
Christina S. Chu et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Toxicity profiles of HER2/neu peptide anticancer vaccines: the picture from Phase I and II clinical trials
Constantin N. Baxevanis et al.
EXPERT REVIEW OF VACCINES (2012)
EGFR/HER-targeted therapeutics in ovarian cancer
Jason A. Wilken et al.
FUTURE MEDICINAL CHEMISTRY (2012)
HER2/neu as a Potential Target for Immunotherapy in Gynecologic Carcinosarcomas
Federica Guzzo et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2012)
被撤回的出版物: Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer (Retracted article. See vol. 129, pg. 2595, 2019)
Holbrook E. Kohrt et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
HER2 expression in ovarian carcinoma: caution and complexity in biomarker analysis
Hugh McCaughan et al.
JOURNAL OF CLINICAL PATHOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Overexpression of Class III Beta Tubulin and Amplified HER2 Gene Predict Good Response to Paclitaxel and Trastuzumab Therapy
Minkyu Jung et al.
PLOS ONE (2012)
Fractionated Therapy of HER2-Expressing Breast and Ovarian Cancer Xenografts in Mice with Targeted Alpha Emitting 227Th-DOTA-p-benzyl-trastuzumab
Helen Heyerdahl et al.
PLOS ONE (2012)
Selectively Expanding Subsets of T Cells in Mice by Injection of Interleukin-2/Antibody Complexes: Implications for Transplantation Tolerance
O. Boyman et al.
TRANSPLANTATION PROCEEDINGS (2012)
FcγR2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer
K. Tamura et al.
ANNALS OF ONCOLOGY (2011)
Comparison of HER2 status in primary and paired metastatic sites of gastric carcinoma
C. Bozzetti et al.
BRITISH JOURNAL OF CANCER (2011)
Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer
Mark Barok et al.
CANCER LETTERS (2011)
Genomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
David S. P. Tan et al.
CLINICAL CANCER RESEARCH (2011)
Phase I/II Study of Trastuzumab in Combination With Everolimus (RAD001) in Patients With HER2-Overexpressing Metastatic Breast Cancer Who Progressed on Trastuzumab-Based Therapy
Phuong K. Morrow et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours
Benedict Yan et al.
JOURNAL OF CLINICAL PATHOLOGY (2011)
Targeting the human EGFR family in esophagogastric cancer
Alicia Okines et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Regulatory T Cells Get Their Chance to Shine
Mitch Leslie
SCIENCE (2011)
Immunohistochemical Study of HER2 and TUBB3 Proteins in Extramammary Paget Disease
Akihiro Miyamoto et al.
AMERICAN JOURNAL OF DERMATOPATHOLOGY (2010)
Silver In Situ Hybridization (SISH) For Determination of HER2 Gene Status in Breast Carcinoma Comparison With FISH and Assessment of Interobserver Reproducibility
Bettina G. Papouchado et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2010)
Implication of RICTOR in the mTOR inhibitor-mediated induction of insulin-like growth factor-I receptor (IGF-IR) and human epidermal growth factor receptor-2 (Her2) expression in gastrointestinal cancer cells
Sven A. Lang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2010)
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma
K. El-Sahwi et al.
BRITISH JOURNAL OF CANCER (2010)
Anti-HER2 vaccines: new prospects for breast cancer therapy
Maha Zohra Ladjemi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Ovarian cancer creates a suppressive microenvironment to escape immune elimination
Refika Yigit et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: A Gynecologic Oncology Group study
Gini F. Fleming et al.
GYNECOLOGIC ONCOLOGY (2010)
Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab
Fabrice Andre et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
HER-2/NEU overexpression in vulvar Paget disease: the Yale experience
Christine E. Richter et al.
JOURNAL OF CLINICAL PATHOLOGY (2010)
Ovarian cancer immunotherapy: opportunities, progresses and challenges
Bei Liu et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2010)
Pretargeted 177Lu Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colonic Tumors in Mice
Rafke Schoffelen et al.
JOURNAL OF NUCLEAR MEDICINE (2010)
Emerging Technologies for Assessing HER2 Amplification
Frederique Penault-Llorca et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2009)
HER2 overexpression and amplification is present in a subset of ovarian mucinous carcinomas and can be targeted with trastuzumab therapy
Jessica N. McAlpine et al.
BMC CANCER (2009)
Status of HER1 and HER2 in peritoneal, ovarian and colorectal endometriosis and ovarian endometrioid adenocarcinoma
C. Uzan et al.
VIRCHOWS ARCHIV (2009)
The growth inhibitory effect of lapatinib, a dual inhibitor of EGFR and HER2 tyrosine kinase, in gastric cancer cell lines
Jin Won Kim et al.
CANCER LETTERS (2008)
Prognostic value of hormonal receptors, p53, ki67 and HER2/neu expression in epithelial ovarian carcinoma
Adelaida Garcia-Velasco et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2008)
Trastuzumab treatment in patients with advanced or recurrent endometrial carcinoma overexpressing HER2/neu
Alessandro D. Santin et al.
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2008)
Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
Antonino Musolino et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Immunophenotyping of serous carcinoma of the female genital tract
Sharon Nofech-Mozes et al.
MODERN PATHOLOGY (2008)
HER2 Status in Ovarian Carcinomas: A Multicenter GINECO Study of 320 Patients
Marianne Tuefferd et al.
PLOS ONE (2007)
Human breast cancer cells selected for resistance to trastuzumab in vivo overexpress epidermal growth factor receptor and ErbB Ligands and remain dependent on the ErbB receptor network
Christoph A. Ritter et al.
CLINICAL CANCER RESEARCH (2007)
Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists
M. Dietel et al.
VIRCHOWS ARCHIV (2007)
Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients
Francois Ghiringhelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer
Maurizio Scaltriti et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Heat shock protein 90: the cancer chaperone
Len Neckers
JOURNAL OF BIOSCIENCES (2007)
Sensitivity to pertuzumab (2C4) in ovarian cancer models: cross-talk with estrogen receptor signaling
Peter Mullen et al.
MOLECULAR CANCER THERAPEUTICS (2007)
HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications
J. A. Villella et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
HER-2 is an independent prognostic factor in endometrial cancer: Association with outcome in a large cohort of surgically staged patients
C Morrison et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prognostic, predictive and therapeutic implications of HER2 in invasive epithelial ovarian cancer
Alberto Serrano-Olvera et al.
CANCER TREATMENT REVIEWS (2006)
Use of trastuzumab in the treatment of metastatic endometrial cancer
E Jewell et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Clinical features and outcomes of uterine and ovarian carcinosarcoma
AL Jonson et al.
GYNECOLOGIC ONCOLOGY (2006)
Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism?
L Arnould et al.
BRITISH JOURNAL OF CANCER (2006)
EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma
CA Livasy et al.
GYNECOLOGIC ONCOLOGY (2006)
HER-2/neu and bcl-2 in ovarian carcinoma - Clinicopathologic, immunohistochemical, and molecular study in patients with shorter and longer survival
Maria Rosaria Raspollini et al.
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY (2006)
Predictive factors for response to docetaxel in human breast cancers
Shinzaburo Noguchi
CANCER SCIENCE (2006)
2C4, a monoclonal antibody against HER2, disrupts the HER kinase signaling pathway and inhibits ovarian carcinoma cell growth
N Takai et al.
CANCER (2005)
Inhibiting complement regulators in cancer immunotherapy with bispecific mAbs
KA Gelderman et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2005)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Assessment of Her-1, Her-2, and Her-3 expression and Her-2 amplification in advanced stage ovarian carcinoma
CH Lee et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2005)
Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): A major prognostic indicator in uterine serous papillary cancer
AD Santin et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2005)
Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing
M Schmidt et al.
BREAST CANCER RESEARCH (2005)
The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells
R Nahta et al.
CANCER RESEARCH (2004)
Blockade of epidermal growth factor- or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects
JG Jackson et al.
CANCER RESEARCH (2004)
Analysis of HER-2/neu amplification in endometrial carcinoma by chromogenic in situ hybridization.: Correlation with fluorescence in situ hybridization, HER-2/neu, p53 and KI-67 protein expression, and outcome
G Peiró et al.
MODERN PATHOLOGY (2004)
Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
R Gennari et al.
CLINICAL CANCER RESEARCH (2004)
Role of HER receptors family in development and differentiation
P Casalini et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2004)
Her-2/neu overexpression and amplification in uterine papillary serous carcinoma
BM Slomovitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
The immunobiology of cancer immunosurveillance and immunoediting
GP Dunn et al.
IMMUNITY (2004)
Her-2/neu expression and amplification in early stage ovarian surface epithelial neoplasms
Y Wu et al.
GYNECOLOGIC ONCOLOGY (2004)
Subclassification of ovarian surface epithelial tumors based on correlation of histologic and molecular Pathologic data
CB Gilks
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma
H Lassus et al.
GYNECOLOGIC ONCOLOGY (2004)
HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group
S Camilleri-Broet et al.
ANNALS OF ONCOLOGY (2004)
Integrated genomic and proteomic analyses of gene expression in mammalian cells
Q Tian et al.
MOLECULAR & CELLULAR PROTEOMICS (2004)
A comparison of the in vitro and in vivo activities of IgG and F(ab′)2 fragments of a mixture of three monoclonal anti-Her-2 antibodies
CI Spiridon et al.
CLINICAL CANCER RESEARCH (2004)
Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling
AD Santin et al.
BRITISH JOURNAL OF CANCER (2004)
Selection of HER-2/neu-positive tumor cells in early stage cervical cancer: implications for Herceptin-mediated therapy
S Bellone et al.
GYNECOLOGIC ONCOLOGY (2003)
Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: A phase II trial of the Gynecologic Oncology Group
MA Bookman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases
BM Slomovitz et al.
GYNECOLOGIC ONCOLOGY (2003)
Different expression patterns of KIT, EGFR, and HER-2 (c-erbB-2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma
M Sawada et al.
CANCER SCIENCE (2003)
HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: Possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab
M Fujimura et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2002)
Paget's disease of the vulva
S Tebes et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2002)
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
DB Agus et al.
CANCER CELL (2002)
Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?
WG McCluggage
JOURNAL OF CLINICAL PATHOLOGY (2002)
The inhibitory effect of CD46, CD55, and CD59 on complement activation after immunotherapeutic treatment of cervical carcinoma cells with monoclonal antibodies or bispecific monoclonal antibodies
KA Gelderman et al.
LABORATORY INVESTIGATION (2002)
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
A Maloney et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Improving the efficacy of antibody-based cancer therapies
P Carter
NATURE REVIEWS CANCER (2001)
Biomarker conservation in primary and metastatic epithelial ovarian cancer
KS Tewari et al.
GYNECOLOGIC ONCOLOGY (2000)
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
RA Clynes et al.
NATURE MEDICINE (2000)
HER-2/neu assessment in breast cancer by immunohistochemistry and fluorescence in situ hybridization: Comparison of results and correlation with survival
S Kakar et al.
MOLECULAR DIAGNOSIS (2000)
Share Paper
